US End-of-Day Verdict 4 Aug 2026, 16:00:00 GMT-4

Sector ETFs — End-of-Day Verdict

NO ACTION -- 0 ACQUIRE, 0 DISPOSE, 1 QUEUE WITHDRAWN. First session in twelve where every candidate fails for a reason the book can name in one line, and where the declines are not all one gate. XLF (adj 98, highest on the board) fails the ARITHMETIC GATE, not the floor: repriced to the buy-stop the live row prints, buys a new all-time high with a 3.56% / 3.00 ATR stop against forwards of -0.12% / +0.15% / -2.54%; fourth consecutive session of under-participation (+0.21% on a record Dow day) while the label printed 90, 100, 98. XLV (adj 73) clears the floor and fails on forecast + geometry: all three Est_* sit BELOW the entry (-0.29% / -0.29% / -3.85%) and the stop at is EXACTLY the session low, 0.53 ATR, in the family whose stop_first_rate is 0.70 -- LLY's +48% revenue quarter and XLV's record highs are real and do not repair that. IBB (adj 64) MISSES THE FLOOR BY ONE POINT and is the best-constructed row on the board -- the only clean ascending forward ladder (SE-2 does not fire), 4.00:1 vs its stop; the floor is a hard bar and is not waived for a good story, but it is armed at raw conviction >= 69. All four BUY - ANTICIPATE names (XLK 82/72, DIA 80/70, XLI 78/68, SPY 65/55) are SLOT-INELIGIBLE on the same rule -- each printed anticipation for the FIRST time today, where >=2 is required -- and all four independently fail the gate (XLK 9.59% stop vs +4.33%, DIA 4.11% vs +0.11%, XLI 5.08% vs +0.55%, SPY 4.10% vs -0.97%). DISPOSE: book is flat, nothing to trim or exit. Aug-5 tape was a clean defensive rotation -- Dow +0.49% to a record 54,349.12 while the Nasdaq snapped a 4-day rally (-0.83%), GLD +4.14% (the largest move on the board, printed NO TRADE cv0), XLV +1.27%, IBB +0.87%, XBI +0.74% against XLE -2.07%, SOXX -2.12% round-tripping yesterday's +6.80%, UFO -2.06%, QTUM -1.93%. Yesterday's own framing was confirmed rather than merely honest: 'if the limit does not fill there was nothing to make' -- it did not fill, and there was nothing to make. : committed, intact.

Latest & archive All books

Recommendations

0 to acquire · 0 to dispose

Ticker	Name	Close	Action	Action Price Where to act — a buy-limit on a pullback or a buy-stop above resistance, not the current price. Sanity-check vs Close: on a held name, an action price stranded above the close means the queued level was set when the stock was higher — stale, awaiting reprice.	Stop The risk-defined exit, set below the entry for a long (~1.2–1.8×ATR). A held long whose Stop sits at/above the Close is already below its stop — a stale box awaiting reprice.	1wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close.	4wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close.	12wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close.	Rationale
IBB	iShares Biotech ETF	191.80	WATCH	191.80	189.90	191.83 (+0.0%)	193.35 (+0.8%)	200.37 (+4.5%)	Two things about biotech today, and the second is the more frustrating. First, the purchase proposed on 30 July was stopped out on its very first session and the book STILL has not recorded whether it was actually taken -- until that is written down the cash position is uncertain by roughly and the outcome cannot be graded honestly; this is the fourth session of that gap. Second, biotech is now the best-shaped opportunity on the whole board -- it is the only fund today whose one-week, four-week and twelve-week forecasts each step higher than the last and all sit above the current price, offering about four dollars of expected gain for every dollar risked -- and it misses the quality bar by a single point. The bar is not bent for a good story, so no purchase, but it is armed to trigger on any improvement. OPS: ADR-0019 UNRECONCILED, FOURTH consecutive session, managed_by human. Original card BUY 65 @189.96 market, execute_on 2026-07-31, stop 185.75; stopped out on the execution session (opened 189.14 = -0.43% gap inside the band so the order stood, low 184.78 through the stop, close 186.41). If TAKEN: -1.79%, -on, If SKIPPED: full Portfolio JSON still shows and the monitor reports trades_detected empty, so the carried default is NOT TAKEN -- an inference from an unchanged file, not a recorded decision; this run was unattended and could not ask. RESOLVE WITH: trade buy, or trade skip sectoretf IBB. Direction none so this line cannot contaminate the cells or calibration -- the 07-30 buy line remains the graded record. TODAY: BUY conv 68 (trail W49 -> W42 -> W57 -> B68), bias -4 (SE-1 live) -> adj 64, MISSES THE 65 FLOOR BY ONE POINT. Buy_Rank 3, +0.87% to 191.80, RSI 58.3, market entry, Entry_Distance_ATR 0.0. ONLY CLEAN ASCENDING FORWARD LADDER ON THE BOARD -- Est_1W 191.83 (+0.02%), Est_4W 193.35 (+0.81%), Est_12W 200.37 (+4.47%), each above the last and all above entry, so SE-2 does NOT fire (systemic finding 4). Target_Price 199.40 vs stop 189.90 = 4.00:1. Stop is 0.50 ATR (the FailedBreakdown cohort defect, systemic finding 1). RE-ARM TRIGGER for the next EOD: raw conviction >= 69 clears the 65 floor after the live -4 haircut. · news

Outcome & track record

Accuracy at the time of this record.

28 Graded decisions Past recommendations old enough to score against what actually happened (target hit / stopped out / closed). This is the evidence base — the bigger the number, the more history behind the calls. Click to inspect every one. See the decisions →

-0.068 1-week calibration How much of the eventual 4-week move typically shows up in the first week (0 = almost none, 1 = most of it). Use it to read the 1-week estimates: a low number means prices drift toward the target slowly, so don't over-read a soft week-1.

50 Published records How many dated end-of-day verdicts exist for this book — the length of the public track record you can browse in the Archive below.

Earlier record 4 August 2026 1 ACQUIRE (QUEUED), 0 DISPOSE -- the bar did not move, the board did. XLF: STRONG BUY at conviction 100, the engine's maximum, on a fifth consecutive buy print with the trail running -> -> 100 and momentum doubling from; queued as a GTC limit at for, 2.31% below the close and just above the anchored VWAP -- the deepest genuine discount on the board -- with a properly-sized 1.17 ATR stop at and 1.99:1 to the objective. It is the ONLY one of seven bullish candidates to pass the arithmetic gate, and it passes at two tenors rather than one. The other six fail in two clean ways: XLI (cv100), DIA (cv90), IWM (cv73) and SPY (cv70) all print 2.20 ATR stops 3.2-4.0% away against forward estimates of at most +1.6%, while XLP (adj 63) and SKYY (63) fall below the conviction floor and MAGS fails the anticipate-slot's 2-of-3 test. Yesterday's two queues both went unfilled and are now split rather than rolled: XLF is REPRICED to the level the live row prints, because everything that justified it got stronger; SPY is WITHDRAWN, because everything that justified it got weaker -- conviction, the family changed to BreakoutUp_52W, the order type changed to a buy-stop the price has already run past, and the stale limit is 3.29% out-of-the-money on a name at a record high. That halves the commitment to (25.0% of the) and removes the SPY/XLF correlation problem entirely. The uncomfortable fact is recorded rather than smoothed: XLF printed the maximum conviction on a session where it gained 0.87% against the S&P's 1.79%, its third straight session of lagging, and it is the worst S&P sector of 2026 -- the book resolves that by refusing to pay the market price, and by time-boxing the trade as a four-week swing since the 12-week estimate is negative for a sixth straight session. The tape was a record-high semiconductor day (PHLX +6%, Marvell +14%, Intel +10%, Palantir +30%) on which this book's own semis complex ended a five-session blackout by printing a BEARISH label at conviction 76 and 69 -- a finding, not a trade. Nothing is spent unless financials mean-revert 2.31% to the limit, and nothing is lost if it expires 08-07 unfilled. The book remains UNRECONCILED for a third session on the 07-30 IBB card, which must be recorded TAKEN or SKIPPED. Later record 6 August 2026 1 ACQUIRE, 0 DISPOSE. BUY 102 IBB @ at the 2026-08-07 open, stop, of (39.4%). Thirteen sessions of declines ended on the one name the book had already committed IN WRITING to buying at a specific unmet threshold: the 08-05 card recorded 'IBB re-arms on raw conviction >= 69' and today IBB printed raw 75, Buy_Rank 1, adj 71 after the live SE-1 -4 haircut -- clearing the 65 floor by six rather than missing it by one. THE GATE WAS NOT RELAXED, THE SETUP IMPROVED THROUGH IT. IBB is the only row on the board whose forward ladder ascends (Est_1W 193.21 / Est_4W 193.13 / Est_12W 203.03, all above the 192.97 entry, SE-2 does not fire) for a second straight session, at 4.00:1 against its stop, not extended (Entry_Distance_ATR 0.0), RSI 60.1, 3% below its 52W high. News CONFIRMS with a fund-flow basis rather than a headline: healthcare +11.2% over three months to a record vs the S&P's +6%, 44bn into US healthcare funds in July after 5bn in June reversing three months of outflows, biotech near one-year highs on decade-high M&A and 46 FDA approvals, at 24.4x forward earnings vs the market's 27.8x. The weakness is stated plainly: the 0.50-ATR stop sits under today's low in a family that stops out first 70% of the time, and it is the SAME construction that killed the 07-30 IBB card on its execution session. DECLINES: XLV (adj 71, TIES IBB and clears the floor) fails the arithmetic gate for a second session -- best forward +0.14% at 4wk against a 0.95% stop, Est_1W -0.24%, Est_12W -3.78% BELOW the entry, SE-2 fires; the same healthcare flows argue for it and cannot repair its own negative forward ladder. DIA (adj 62) falls below the floor for the first time in six sessions as the Dow gave back 388 points off its record on rising yields (claims 199k, July layoffs a two-year low); the gate fails independently. XLF is not a near-miss but a VINDICATION -- conviction 98 -> NO TRADE 0 in one session with Momentum flipping Bearish, so yesterday's withdrawal saved the book from owning a zero-rated position bought 0.6% above the current price. All four of the 08-05 ANTICIPATE names collapsed (XLK, DIA, XLI, SPY over three sessions) -- none repeated the print, so none could ever have reached 2-of-3, and the slot-eligibility rule was correct, not merely defensible. DXYZ was the day's biggest move (+5.61% on FTSE fast-tracking index entry ahead of the SpaceX IPO) and stays AVOID: it is the only priced row in the book and it reads OVERVALUED_VS_RI, MoS -0.78, Quality_Pass False, a closed-end fund at a large premium to NAV. DISPOSE: book is flat, nothing to trim or exit. Aug-6 tape: Dow -387.67 to 53,961.45 off its record, S&P -5.72 to 7,718.05, Nasdaq Composite +11.48 to 26,374.92; DXYZ +5.61%, XLE +1.48% (round-tripping yesterday's -2.07% on the same unresolved Hormuz story), XBI +0.97%, IBB +0.61% against SKYY -1.88%, XLI -0.85%, DIA -0.85%, AIQ -0.66%. : committed, remaining, self-financed.